PMID- 28938692
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20170925
LR  - 20220408
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 35
DP  - 2017 Aug 29
TI  - Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid 
      tumors: a systematic review and meta-analysis.
PG  - 59901-59914
LID - 10.18632/oncotarget.18316 [doi]
AB  - BACKGROUND: PD-1/PD-L1 inhibitors have been implicated as potentially effective 
      anti-cancer therapies. Some clinical randomized controlled trials (RCTs) have 
      been completed for a variety of PD-1/PD-L1 inhibitors to treat various 
      malignancies, and more RCTs are still under way. We carried out this systematic 
      meta-analysis to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the 
      treatment of solid tumors. METHODS: We searched PubMed, EMBASE, clinical trial 
      registers, conference reports, and related reviews. Eligible RCTs that compared 
      PD-1/PD-L1 inhibitors with other chemotherapy agents or placebo in solid tumor 
      patients were included. For each RCT, progression-free survival (PFS), overall 
      survival (OS), objective response rate (ORR), disease control rate (DCR), stable 
      disease rate (SDR), progressive disease rate (PDR), and adverse events (AEs) were 
      pooled for meta-analysis. FINDINGS: Based on an analysis of 10 eligible RCTs, 
      PD-1/PD-L1 inhibitors were found to significantly improve PFS (Hazard ratio (HR), 
      0.65; 95% confidence interval (CI) 0.53 to 0.79, P<0.001), OS (HR, 0.69; 95%CI 
      0.62 to 0.76, P<0.001), and ORR (Risk Ratio (RR) 292; 95% confidence interval 
      (CI) 2.06 to 4.15, P<0.00001) in all populations, including melanoma and NSCLC 
      subgroups. However, they failed to increase the DCR of cancer patients (RR 1.15; 
      95%CI 0.91 to 1.45, P=0.25). Furthermore, less AEs were observed in the 
      PD-1/PD-L1 inhibitor groups than the control groups. INTERPRETATION: PD-1 
      inhibitors are more effective for improving the PFS, OS, and ORR of cancer 
      patients with little toxicity, despite having little effect on increasing of the 
      DCR.
FAU - Wang, Xiaohui
AU  - Wang X
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
AD  - Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, 
      China.
FAU - Bao, Zhengqiang
AU  - Bao Z
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
AD  - Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, 
      China.
FAU - Zhang, Xiaoju
AU  - Zhang X
AD  - Department of Respiratory Medicine, Zhengzhou University People's Hospital, Henan 
      Provincial People's Hospital, Zhengzhou, China.
FAU - Li, Fei
AU  - Li F
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Lai, Tianwen
AU  - Lai T
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Cao, Chao
AU  - Cao C
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Chen, Zhihua
AU  - Chen Z
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Li, Wen
AU  - Li W
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Shen, Huahao
AU  - Shen H
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
AD  - State Key Laboratory of Respiratory Diseases, Guangzhou, China.
FAU - Ying, Songmin
AU  - Ying S
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
AD  - Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170531
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5601788
OTO - NOTNLM
OT  - PD-1
OT  - PD-L1
OT  - cancer
OT  - nivolumab
OT  - pembrolizumab
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest in this work.
EDAT- 2017/09/25 06:00
MHDA- 2017/09/25 06:01
PMCR- 2017/08/29
CRDT- 2017/09/24 06:00
PHST- 2016/08/12 00:00 [received]
PHST- 2017/03/01 00:00 [accepted]
PHST- 2017/09/24 06:00 [entrez]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2017/09/25 06:01 [medline]
PHST- 2017/08/29 00:00 [pmc-release]
AID - 18316 [pii]
AID - 10.18632/oncotarget.18316 [doi]
PST - epublish
SO  - Oncotarget. 2017 May 31;8(35):59901-59914. doi: 10.18632/oncotarget.18316. 
      eCollection 2017 Aug 29.